Your browser doesn't support javascript.
loading
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.
Tyagi, Anudishi; Jaggupilli, Appalaraju; Ly, Stanley; Yuan, Bin; El-Dana, Fouad; Hegde, Venkatesh L; Anand, Vivek; Kumar, Bijender; Puppala, Mamta; Yin, Zheng; Wong, Stephen T C; Mollard, Alexis; Vankayalapati, Hariprasad; Foulks, Jason M; Warner, Steven L; Daver, Naval; Borthakur, Gautam; Battula, V Lokesh.
Afiliação
  • Tyagi A; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jaggupilli A; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ly S; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yuan B; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • El-Dana F; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hegde VL; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Anand V; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kumar B; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Puppala M; Department of Systems Medicine and Bioengineering, Houston Methodist Neal Cancer Center, Weill Cornell Medicine, Houston, TX, USA.
  • Yin Z; Department of Systems Medicine and Bioengineering, Houston Methodist Neal Cancer Center, Weill Cornell Medicine, Houston, TX, USA.
  • Wong STC; Department of Systems Medicine and Bioengineering, Houston Methodist Neal Cancer Center, Weill Cornell Medicine, Houston, TX, USA.
  • Mollard A; University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
  • Vankayalapati H; University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
  • Foulks JM; Sumitomo Pharma Oncology, Inc, Lehi, UT, USA.
  • Warner SL; Sumitomo Pharma Oncology, Inc, Lehi, UT, USA.
  • Daver N; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Borthakur G; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Battula VL; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vbattula@mdanderson.org.
Leukemia ; 38(1): 82-95, 2024 01.
Article em En | MEDLINE | ID: mdl-38007585
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article